The continuous manufacturing market is projected to grow at an annualized rate of over 15%, till 2030(Roots Analysis)
Roots Analysis has done a detailed study on ManufacturingMarket Continuous (Small Molecules and Biologics), 2020 – 2030.”, covering keyaspects of the industry and identifying future growth opportunities.
To order this 310+ page report, which features 110+ figuresand 200+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/continuous-manufacturing/308.html
Key Market Insights
§ Eminentrepresentatives from prominent contract service provider companies /organizations are both optimistic and cautious regarding the rising interest incontinuous flow technologies, and its adoption
§ Over 60 companiesacross the globe claim to manufacture drug products / drug substances using thecontinuous manufacturing technique, either for in-house requirements or forcontract service engagements
§ The market landscapefeatures the presence of several well-established players, most of which claimto manufacture small molecules via the continuous technique, and are based inthe developed geographies
§ Companies have established continuous drug manufacturing facilities fordiverse types of dosage forms in various geographies; Europe and North Americahave emerged as the key hubs for these facilities
§ Several patents havebeen filed / granted specifically related to continuous manufacturing ofpharmaceutical substances, both industry and non-industry players are activelyinvolved in such efforts
§ Organizations havealso extended financial support to aid the research efforts being put byvarious stakeholders in this domain; the current focus is on investigation ofcontinuous manufacturing technologies
§ Over time, there has been a lot of activity in this arena, including theestablishment of several partnerships and investments in capability andcapacity expansions and new facilities worldwide
§ Most of thecontinuous manufacturing capacity belongs to established companies (in-housemanufacturers and CMOs), accounting for over 70% of the available capacityacross various geographies
§ Involvement of various other stakeholders including continuous equipmentproviders and modular facility providers is likely to revolutionize the overallmanufacturing domain
§ As the adoption ofcontinuous manufacturing technologies increases, the market is likely towitness significant growth; in the short term, majority of service-basedrevenues is likely to come from drug product related projects
For more information, please visit https://www.rootsanalysis.com/reports/view_document/continuous-manufacturing/308.html
Table of Contents
TABLEOF CONTENTS
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Historical Evolution of ContinuousManufacturing
3.3. Continuous Manufacturing in thePharmaceutical Industry
3.3.1. Regulatory Landscape
3.3.2. Early Adopters of Continuous Manufacturing
3.3.3. Anticipated Shift to ContinuousManufacturing
3.3.4. Advantages of Continuous Manufacturing
3.3.5. Key Challenges Associated with ContinuousManufacturing
3.3.6. Future Perspectives
4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Companies with Expertise in ContinuousManufacturing: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Purpose of Manufacturing
4.2.4. Analysis by Scale of Operation
4.2.5. Analysis by Location of Headquarters
4.2.6. Analysis by Location of ContinuousManufacturing Facilities
4.2.7. Analysis by Type of Drug Molecule
4.2.8. Analysis by Type of Continuous ManufacturingRelated Service
4.2.9. Analysis by Type of Dosage Form
4.2.10. Heat Map: Analysis by Company Size andLocation of Headquarters
4.2.11. Information on Production Capacity
4.2.12. Logo Landscape: Analysis by Year ofEstablishment and Company Size
4.2.13. Grid Representation: Analysis by Scale ofOperation, Type of Continuous Manufacturing Related Service and Type of DosageForm
4.2.14. Geographical Map: Analysis by Location ofContinuous Manufacturing Facilities and Type of Drug Molecule
5. COMPANIES WITH EXPERTISE IN CONTINUOUSMANUFACTURING IN NORTH AMERICA: PROFILES
5.1. Chapter Overview
5.2. AbbVie Contract Manufacturing
5.2.1. Company Overview
5.2.2. Service Portfolio
5.2.3. Continuous Manufacturing Capabilities andFacilities
5.2.4. Recent Developments and Future Outlook
5.3. Cambrex
5.3.1. Company Overview
5.3.2. Service Portfolio
5.3.3. Continuous Manufacturing Capabilities andFacilities
5.3.4. Recent Developments and Future Outlook
5.4. Patheon
5.4.1. Company Overview
5.4.2. Service Portfolio
5.4.3. Continuous Manufacturing Capabilities andFacilities
5.4.4. Recent Developments and Future Outlook
5.5. SK biotek
5.5.1. Company Overview
5.5.2. Service Portfolio
5.5.3. Continuous Manufacturing Capabilities andFacilities
5.5.4. Recent Developments and Future Outlook
6. COMPANIES WITH EXPERTISE IN CONTINUOUSMANUFACTURING IN EUROPE: PROFILES
6.1. Chapter Overview
6.2. Ajinomoto Bio-Pharma Services
6.2.1. Company Overview
6.2.2. Service Portfolio
6.2.3. Continuous Manufacturing Capabilities andFacilities
6.2.4. Recent Developments and Future Outlook
6.3. Almac
6.3.1. Company Overview
6.3.2. Service Portfolio
6.3.3. Continuous Manufacturing Capabilities andFacilities
6.3.4. Recent Developments and Future Outlook
6.4. Boehringer Ingelheim BioXcellence™
6.4.1. Company Overview
6.4.2. Service Portfolio
6.4.3. Continuous Manufacturing Capabilities andFacilities
6.4.4. Recent Developments and Future Outlook
6.5. CordonPharma
6.5.1. Company Overview
6.5.2. Service Portfolio
6.5.3. Continuous Manufacturing Capabilities andFacilities
6.5.4. Recent Developments and Future Outlook
6.6. Hovione
6.6.1. Company Overview
6.6.2. Service Portfolio
6.6.3. Continuous Manufacturing Capabilities andFacilities
6.6.4. Recent Developments and Future Outlook
6.7. Lonza
6.7.1. Company Overview
6.7.2. Service Portfolio
6.7.3. Continuous Manufacturing Capabilities andFacilities
6.7.4. Recent Developments and Future Outlook
7. COMPANIES WITH EXPERTISE IN CONTINUOUSMANUFACTURING IN ASIA-PACIFIC: PROFILES
7.1. Chapter Overview
7.2. Kaneka
7.2.1. Company Overview
7.2.2. Service Portfolio
7.2.3. Continuous Manufacturing Capabilities andFacilities
7.2.4. Recent Developments and Future Outlook
7.3. WuXi AppTec
7.3.1. Company Overview
7.3.2. Service Portfolio
7.3.3. Continuous Manufacturing Capabilities andFacilities
7.3.4. Recent Developments and Future Outlook
8. RECENT PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. List of Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Scale of Operation
8.3.4. Analysis by Type of Drug Molecule
8.3.5. Analysis by Type of Continuous ManufacturingRelated Service
8.3.6. Analysis by Type of Dosage Form
8.3.7. Most Active Players: Analysis by Number ofPartnerships
8.3.8. Regional Analysis
8.3.8.1. Intercontinental and IntracontinentalAgreements
9. RECENT EXPANSIONS
9.1. Chapter Overview
9.2. Recent Expansions
9.2.1. Analysis by Year of Expansion
9.2.2. Analysis by Type of Expansion
9.2.3. Analysis by Expanded Scale of Expansion
9.2.4. Analysis by Type of Drug Molecule
9.2.5. Analysis by Type of Continuous ManufacturingRelated Service
9.2.6. Analysis by Type of Dosage Form
9.2.7. Most Active Players: Analysis by Number ofExpansions
9.2.8. Regional Analysis
9.2.8.1. Analysis by Location of Expansion Project
10. CAPACITY ANALYSIS
10.1. Chapter Overview
10.2. Assumptions and Methodology
10.3. Global, Continuous Manufacturing Capacityfor Small Molecule APIs
10.3.1. Analysis by Company Size
10.3.2. Analysis by Purpose of Manufacturing
10.3.3. Analysis by Scale of Operation
10.3.4. Analysis by Location of Headquarters
10.3.4. Analysis by Location of Continuous ManufacturingFacilities
10.4. Global, Continuous Manufacturing Capacityfor Small Molecule End Products
10.4.1. Analysis by Company Size
10.4.2. Analysis by Purpose of Manufacturing
10.4.3. Analysis by Scale of Operation
10.4.4. Analysis by Location of Headquarters
10.4.5. Analysis by Location of ContinuousManufacturing Facilities
10.5. Global, Continuous Manufacturing Capacityfor Biologic
10.5.1. Analysis by Company Size
10.5.2. Analysis by Purpose of Manufacturing
10.5.3. Analysis by Scale of Operation
10.5.4. Analysis by Location of Headquarters
10.5.5. Analysis by Location of ContinuousManufacturing Facilities
11. ACADEMIC GRANT ANALYSIS
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Continuous Manufacturing: List of Academic Grants
11.3.1. Analysis by Number of Grants
11.3.2. Analysis by Activity Code
11.3.3. Analysis by Grant Amount
11.3.4. Analysis by Focus Area
11.3.5. Analysis by Support Period
11.3.6 Popular Recipient Organizations: Analysis byNumber of Grants
11.3.7 Analysis by Type of Recipient Organization
11.3.8. Analysis by Funding Institute Centre
11.3.9. Analysis by Funding Mechanism
11.3.10.Prominent Program Officers: Analysis by Number of Grants
12. PATENT ANALYSIS
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. Continuous Manufacturing: Patent Analysis
12.3.1. Analysis by Publication Year
12.3.2. Analysis by Geography
12.3.3. Analysis by CPC Symbols
12.3.4. Emerging Focus Areas
12.3.5. Analysis by Type of Applicant
12.3.6. Leading Players: Analysis by Number of Patents
12.3.7. Continuous Manufacturing: Three-DimensionalBubble Analysis
12.3.8. Continuous Manufacturing: Patent ValuationAnalysis
12.3.8.1.Leading Patents: Information by Number of Citations
13. INITIATIVES OF COMPANIES WITH IN-HOUSECONTINUOUS MANUFACTURING CAPABILITIES
13.1. Chapter Overview
13.2. Continuous Manufacturing Initiatives ofLeading Companies
13.2.1. AbbVie
13.2.1.1.Partnered Initiatives
13.2.1.2In-House Initiatives
13.2.2. Amgen
13.2.2.1.Partnered Initiatives
13.2.2.2.In-House Initiatives
13.2.3. Bristol-Myers Squibb
13.2.3.1.Partnered Initiatives
13.2.3.2.In-House Initiatives
13.2.4. GlaxoSmithKline
13.2.4.1.Partnered Initiatives
13.2.4.2.In-House Initiatives
13.2.5. Merck
13.2.5.1.Partnered Initiatives
13.2.5.2.In-House Initiatives
13.2.6. Novartis
13.2.6.1.Partnered Initiatives
13.2.6.2.In-House Initiatives
13.2.7. Pfizer
13.2.7.1.Partnered Initiatives
13.2.7.2.In-House Initiatives
13.2.8. Roche
13.2.8.1.Partnered Initiatives
13.2.8.2.In-House Initiatives
13.2.9. Sanofi
13.2.9.1.Partnered Initiatives
13.2.9.2.In-House Initiatives
14. CASE STUDY: MODULAR FACILITIES INPHARMACEUTICAL / BIOTECHNOLOGY INDUSTRY
14.1. Chapter Overview
14.2. Historical Background
14.3. Concept of Modularization
14.3.1. Types of Modules
14.3.2. Modular Construction Process
14.4. Modular Construction in the PharmaceuticalIndustry
14.4.1. Advantages of Modular Construction in thePharmaceutical Industry
14.5. Modular Facility Manufacturers
14.5.1. Distribution by Industry Served
14.5.2. Distribution by Geography
14.5.3. Modular Projects Executed / Undertaken
14.6. Modular Pharmaceutical Cleanrooms
14.6.1. Cleanroom Classification and Current Standards
14.6.2. Advantages of Modular Cleanrooms
14.6.3. Regulations and Standards Concerning ModularCleanroom Construction
14.7. Modular Cleanroom Providers
14.7.1. Distribution by Industry Served
14.7.2. Distribution by Geography
14.7.3. Type of Modular Cleanrooms Offered
15. CASE STUDY: TECHNOLOGY ANDEQUIPMENT PROVIDERS
15.1. Chapter Overview
15.2. Types of Continuous ManufacturingTechnologies
15.3. Equipment and Technologies for ContinuousManufacturing Small Molecules and Biologics
15.3.1. Continuous Blending and Mixing Equipment
15.3.2. Continuous Granulating Equipment
15.3.3. Continuous Drying Equipment
15.3.4. Continuous Compression Equipment
15.3.5. Continuous Coating Equipment
15.3.6. Continuous Filtration, Continuous Distillationand Continuous Centrifugation Equipment
15.3.7. Continuous Chromatography Equipment
15.3.8. Continuous Reactors / Bioreactors
15.3.9. Full Line Continuous Platforms
15.3.10.Process Analytical Technologies
15.3.11.Other Technologies
15.4. Logo Landscape: Analysis of TechnologyProviders by Number and Type of Equipment
16. CASE STUDY: ROADMAP FOR THE ADOPTION OFCONTINUOUS MANUFACTURING PROCESSES
16.1. Chapter Overview
16.2. Key Strategies for the Adoption ofContinuous Manufacturing Processes
16.2.1. Phase I: Process Development and Implementation
16.2.2. Phase II: Equipment / TechnologyDevelopment and Installation
16.2.3. Phase III: Facility / Plant Developmentand Establishment
16.2.4. Phase IV: Product Development andManufacturing
17. MARKET FORECAST AND OPPORTUNITYANALYSIS
17.1. Chapter Overview
17.2. Forecast Methodology and Key Assumptions
17.3. Overall, Continuous Manufacturing Market,2020-2030
17.3.1. Continuous Manufacturing Market: Distributionby Purpose of Manufacturing, 2020-2030
17.3.2. Continuous Manufacturing Market: Distributionby Scale of Operation, 2020-2030
17.3.3. Continuous Manufacturing Market: Distributionby Type of Drug Molecule, 2020-2030
17.3.4. Continuous Manufacturing Market: Distributionby Type of Continuous Manufacturing Related Service, 2020-2030
17.3.5. Continuous Manufacturing Market: Distributionby Type of Dosage Form, 2020-2030
17.3.6. Continuous Manufacturing Market: Distributionby Key Geographical Regions, 2020-2030
17.4. Continuous Manufacturing Market for SmallMolecule, 2020-2030
17.4.1. Distribution by Purpose of Manufacturing,2020-2030
17.4.2. Distribution by Scale of Operation, 2020-2030
17.4.3. Distribution by Type of ContinuousManufacturing Related Service, 2020-2030
17.4.4. Distribution by Key Geographical Regions,2020-2030
17.5. Continuous Manufacturing Market forBiologic, 2020-2030
17.5.1. Distribution by Purpose of Manufacturing,2020-2030
17.5.2. Distribution by Scale of Operation, 2020-2030
17.5.3. Distribution by Type of ContinuousManufacturing Related Service, 2020-2030
17.5.4. Distribution by Key Geographical Regions,2020-2030
18. CONCLUSION
18.1. Chapter Overview
18.2. Key Takeaways
19. EXECUTIVE INSIGHTS
19.1. Chapter Overview
19.2. Zaiput Flow Technologies
19.2.1. Company Snapshot
19.2.2. Interview Transcript: Andrea Adamo, Founderand Chief Executive Officer
19.3. CONTINUUS Pharmaceuticals
19.3.1. Company Snapshot
19.3.2. Interview Transcript: Bayan Takizawa,Co-Founder and Chief Business Officer
19.4. Snapdragon Chemistry
19.4.1. Company Snapshot
19.4.2. Interview Transcript: Eric Fang, ChiefScientific Officer
19.5. Enzene Biosciences
19.5.1. Company Snapshot
19.5.2. Interview Transcript: Himanshu Gadgil,Director and Chief Scientific Officer
19.6. Pfizer
19.6.1. Company Snapshot
19.6.2. Interview Transcript: Nick Thomson, SeniorDirector Chemical Research and Development
19.7. University of Strathclyde
19.7.1. Company Snapshot
19.7.2. Interview Transcript: Ian Houson, TechnicalProject Manager
20. APPENDIX 1: TABULATED DATA
21. APPENDIX 2: LIST OF COMPANIES ANDORGANIZATIONS
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
